Glucotrack, Inc. (GCTK) Form 8-K — Oct 19, 2026
Glucotrack entered into a Waiver Agreement on October 13, 2026 with holders of warrants issued under its July 14, 2026 Securities Purchase Agreement. In exchange for the waivers, the company must issue New Warrants to purchase an aggregate of 406,198 shares at a $7.50 exercise price, expiring five years from issuance. The waivers terminate the restriction on the company's ability to issue new equity under Section 5.10(a) of the Purchase Agreement and eliminate the warrant exercise-price ratchet triggered by variable rate transactions. This frees Glucotrack to pursue new financings without triggering price resets, though the holders extracted new warrants as compensation.
Key figures
- Floor price
- 20% of closing sale price on issuance date
- New warrant shares
- 406198
- Warrant term years
- 5
- Warrant exercise price
- 7.5
- Beneficial ownership limit
- 9.99%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.